Mortality and Productivity Losses From Alzheimer Disease Among US Adults Aged 40 to 64 Years, 1999 to 2010

Moschetti, Kristin; Barragan, Noel; Basurto‐Dávila, Ricardo; Cummings, Patricia L.; Sorvillo, Frank; Kuo, Tony

doi:10.1097/wad.0000000000000017

Cited by 15 publications

(9 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Productivity losses are also challenging to assess and compare across different studies due to several potential confounding factors such as differences in stages of illness in the populations examined, country-specific differences in labor marker wages or differences in the methods used in calculating costs. For example, one study estimated productivity losses due to premature mortality from AD based on US death certificates from 1999 to 2010 [76]. Using a human capital approach, the cost due to premature mortality was $4.4 billion (2010 US dollars) over the period 1999 to 2010 [76].…”

Section: Patients: Productivity Lossesmentioning

confidence: 99%

“…For example, one study estimated productivity losses due to premature mortality from AD based on US death certificates from 1999 to 2010 [76]. Using a human capital approach, the cost due to premature mortality was $4.4 billion (2010 US dollars) over the period 1999 to 2010 [76]. While non-trivial, this pales in comparison to the total cost of ADRD, which has been estimated at US$259 billion in the US in 2016 alone [77].…”

Section: Patients: Productivity Lossesmentioning

confidence: 99%

See 1 more Smart Citation

Tip of the Iceberg: Assessing the Global Socioeconomic Costs of Alzheimer’s Disease and Related Dementias and Strategic Implications for Stakeholders

El-Hayek¹,

Wiley

Khoury³

et al. 2019

JAD

167

135

View full text Add to dashboard Cite

While it is generally understood that Alzheimer's disease (AD) and related dementias (ADRD) is one of the costliest diseases to society, there is widespread concern that researchers and policymakers are not comprehensively capturing and describing the full scope and magnitude of the socioeconomic burden of ADRD. This review aimed to 1) catalogue the different types of AD-related socioeconomic costs described in the literature; 2) assess the challenges and gaps of existing approaches to measuring these costs; and 3) analyze and discuss the implications for stakeholders including policymakers, healthcare systems, associations, advocacy groups, clinicians, and researchers looking to improve the ability to generate reliable data that can guide evidence-based decision making. A centrally emergent theme from this review is that it is challenging to gauge the true value of policies, programs, or interventions in the ADRD arena given the long-term, progressive nature of the disease, its insidious socioeconomic impact beyond the patient and the formal healthcare system, and the complexities and current deficiencies (in measures and real-world data) in accurately calculating the full costs to society. There is therefore an urgent need for all stakeholders to establish a common understanding of the challenges in evaluating the full cost of ADRD and define approaches that allow us to measure these costs more accurately, with a view to prioritizing evidence-based solutions to mitigate this looming public health crisis.

show abstract

Section: Patients: Productivity Lossesmentioning

confidence: 99%

Section: Patients: Productivity Lossesmentioning

confidence: 99%

Tip of the Iceberg: Assessing the Global Socioeconomic Costs of Alzheimer’s Disease and Related Dementias and Strategic Implications for Stakeholders

El-Hayek¹,

Wiley

Khoury³

et al. 2019

JAD

167

135

View full text Add to dashboard Cite

show abstract

“…24 Similar methods to assess productivity losses using MCD data have been published in the literature. 25,26 …”

Section: Methodsmentioning

confidence: 99%

Trends, Productivity Losses, and Associated Medical Conditions Among Toxoplasmosis Deaths in the United States, 2000–2010

Cummings¹,

Kuo²,

Javanbakht³

et al. 2014

The American Society of Tropical Medicine and Hygiene

Self Cite

View full text Add to dashboard Cite

Abstract. Few studies have quantified toxoplasmosis mortality, associated medical conditions, and productivity losses in the United States. We examined national multiple cause of death data and estimated productivity losses caused by toxoplasmosis during 2000-2010. A matched case-control analysis examined associations between comorbid medical conditions and toxoplasmosis deaths. In total, 789 toxoplasmosis deaths were identified during the 11-year study period. Blacks and Hispanics had the highest toxoplasmosis mortality compared with whites. Several medical conditions were associated with toxoplasmosis deaths, including human immunodeficiency virus (HIV), lymphoma, leukemia, and connective tissue disorders. The number of toxoplasmosis deaths with an HIV codiagnosis declined from 2000 to 2010; the numbers without such a codiagnosis remained static. Cumulative disease-related productivity losses for the 11-year period were nearly $815 million. Although toxoplasmosis mortality has declined in the last decade, the infection remains costly and is an important cause of preventable death among non-HIV subgroups.

show abstract

“…Unfortunately, EOAD is often atypical and missed, resulting in about a 1.6 year average delay in diagnosis compared to older patients 8 . Yet, from 1999 to 2010, mortality reports show that EOAD accounted for a large number of premature deaths among US adults aged 40–64 with many years of potential life lost as well as losses in productivity 9 .…”

Section: Introductionmentioning

confidence: 99%

Early-Onset Alzheimer Disease

2017

View full text Add to dashboard Cite

SYNOPSIS Early-onset Alzheimer’s disease (EOAD) with onset <65 years of age, while overshadowed by the more common late-onset AD (LOAD), differs significantly from LOAD. EOAD comprises about 5% of AD and is associated with delays in diagnosis, an aggressive course, and age-related psychosocial needs. One source of confusion is that a substantial percentage of EOAD are phenotypic variants that differ from the usual memory-disordered presentation of typical AD. Patients with EOAD overall have greater parietal atrophy, more white matter abnormalities, and less hippocampal volume loss, compared to those with LOAD. The phenotypic variants also have atrophy and white matter changes corresponding anatomically to the cognitive changes and appear to involve alternate neural networks relative to typical AD. The management of EOAD is similar to that for LOAD but special emphasis should be placed on targeting the specific cognitive areas involved and more age-appropriate psychosocial support and education.

show abstract

Mortality and Productivity Losses From Alzheimer Disease Among US Adults Aged 40 to 64 Years, 1999 to 2010

Cited by 15 publications

References 7 publications

Tip of the Iceberg: Assessing the Global Socioeconomic Costs of Alzheimer’s Disease and Related Dementias and Strategic Implications for Stakeholders

Tip of the Iceberg: Assessing the Global Socioeconomic Costs of Alzheimer’s Disease and Related Dementias and Strategic Implications for Stakeholders

Trends, Productivity Losses, and Associated Medical Conditions Among Toxoplasmosis Deaths in the United States, 2000–2010

Early-Onset Alzheimer Disease

Contact Info

Product

Resources

About